1NIH Consensus Development Panel on Osteoporosis Prevention.Diagnosis and Therapy.JAMA,2001,285:785-795.
2Heaney RP.Is the paradigm shifting.Bone,2003,33:457-465.
3Garnero P,Sornay-Rendu E,Claustrar B,et al.Biochemical markets of bone turnover.endogenous hormones and the risk of fracture in postmenpausal women:the OFELY study.J Bone Minter Res,2000,15:1526-1536.
4Ross PD,Kress BC,Parson RE,et al.Serum bone alkaline phosphatase and calcaneus bone density predict fractures:a prospective study.Ostteoporos Int,2000,11:76-82.
5Shiraki M,Kushida K,Fukunaga M.For the Alendronate Phase ⅡOsteoporosis Research Group.A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with psteoporosis.Ostoporos Int,1999,10:183-192.
6Morii H,Ohashi Y,Taketani Y,et al.Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese potaymenopausal women with osteoprosis:results from a randomized placebo-controlled trial.Osteopros Int,2003,14:793-800.
8Bjarnason NH,Sarker S,Duong T,et al.Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3years of raloxifene treatment in postmenpausal osteoprosis.Osteopros int,2001,12:922-939.
9Eastell R,Barton I,Hannon RA,et al,Relationship of early changes in bone resorption to the reduction in frature risk with risedronate.J Bone Miner Res,2003,18:1051-1056.
3[1]NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis and Therapy. JAMA 2001,285:785-795.
4[2]Weinstein RS. True strength. J Bone Miner Res 2000,15:621-625.
5[3]Chesnut Ⅲ CH, Rosen CJ for the Bone Quality Discussion Group. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 2001,16:2163-2172.
6[4]Marcus R, Wong M, Heath Ⅲ H, et al. Antiresorptive treatment of posrmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Rev 2002,23:16-37.
7[5]Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001,19:331-337.
8[6]Cummings SR, Karpf DB, Harris F, et al. Improvement of spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002,112: 282-289.
9[7]Heaney RP. Is the paradigm shifting? Bone 2003,33:457-465.
10[8]Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women; EPIDOS prospective study. J Bone Mineral Res 1996,11:1531-1538.
